Compare CDW & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDW | BBIO |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | 14800 | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 15.3B |
| IPO Year | 2013 | 2019 |
| Metric | CDW | BBIO |
|---|---|---|
| Price | $118.60 | $69.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 25 |
| Target Price | ★ $164.88 | $83.96 |
| AVG Volume (30 Days) | 1.3M | ★ 1.8M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 1.38 | N/A |
| EPS | ★ 8.08 | N/A |
| Revenue | ★ $10,768,600,000.00 | $502,076,000.00 |
| Revenue This Year | $4.08 | $88.16 |
| Revenue Next Year | $4.01 | $74.13 |
| P/E Ratio | $14.99 | ★ N/A |
| Revenue Growth | 6.32 | ★ 126.26 |
| 52 Week Low | $112.98 | $28.33 |
| 52 Week High | $189.45 | $84.94 |
| Indicator | CDW | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 41.29 | 48.95 |
| Support Level | $112.98 | $61.95 |
| Resistance Level | $127.29 | $78.83 |
| Average True Range (ATR) | 3.36 | 3.02 |
| MACD | 0.56 | 0.39 |
| Stochastic Oscillator | 52.65 | 24.66 |
CDW Corp is a multi-brand provider of information technology (IT) solutions to businesses, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's offerings range from hardware and software products to integrated IT solutions and services, including on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. Its reportable segments are Corporate, Small Business, Public, and Other. The Corporate and Small Business segments serve US private sector business customers, while the Public segment consists of government agencies and education and healthcare institutions in the US. The Corporate segment generates the majority of its revenue in the United States.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.